“Can cancer cells become “normal”? Introducing Rosalind, the ultimate personalised cancer treatment.”




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: “Can cancer cells become “normal”? Introducing Rosalind, the ultimate personalised cancer treatment.”
Released on: September 22, 2014. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Is it possible to transform cells from being cancerous to non cancerous? During BIO 2014 Wayne Danter, CEO of COTI explains to Adrian Dawkes how by using their cancer cell simulation programme it is possible to identify the most appropriate cancer therapies for a specific gene mutation profile.
  • Summary
  • Transcript
  • Participants
  • Company
Is it possible to transform cells from being cancerous to non cancerous? During BIO 2014 Wayne Danter, CEO of COTI explains to Adrian Dawkes how by using their cancer cell simulation programme it is possible to identify the most appropriate cancer therapies for a specific gene mutation profile. Introducing Rosalind - a personalised cancer care tool.
Is it possible to transform cells from being cancerous to non cancerous? During BIO 2014 Wayne Danter, CEO of COTI explains to Adrian Dawkes how by using their cancer cell simulation programme it is possible to identify the most appropriate cancer therapies for a specific gene mutation profile. Introducing Rosalind - a personalised cancer care tool.
Wayne Danter
COTI
Dr. Wayne Danter is a co-founder of Critical Outcome Technologies Inc. and the President and CEO. He is a pioneer in the evolving interface between artificial intelligence (“AI”) and pharmacotherapeutics. Dr. Danter is the inventor of CHEMSAS® - a proprietary, AI-based technology platform, which utilizes a series of predictive computer models to identify compounds with a high probability of being successfully developed from disease specific drug discovery and chemical optimization through preclinical testing. Dr. Danter trained at the University of Western Ontario in Internal Medicine and Clinical Pharmacology. Prior to founding Critical Outcome Technologies, he was an Associate Professor of Medicine at the University of Western Ontario. His clinical focus at the University was in General Cardiology, Cardiovascular Diseases associated with HIV, and Cardiovascular Risk Management. CHEMSAS® stems from Dr. Danter’s initial research focused on the medical application of AI technologies to disease diagnosis and outcome prediction. His research has been published in peer-reviewed publications and he has presented at numerous international meetings. - See more at: http://www.criticaloutcomeblog.com/dr-wayne-danter.html#sthash.zGEfvfom.dpuf
Critical Outcome Technologies Inc
COTI-2 is a novel small molecule that acts by inhibiting Akt/PKB (Protein kinase B) phosphorylation that leads to caspase-9 activation in cancer cells resulting in tumor cell death. COTI-2 has demonstrated greater selectivity as well as an improved safety profile and pharmacokinetics in comparison to other Akt inhibitors. COTI-2 is easily synthesized and has good in vitro and in vivo efficacy against multiple human cancers including small cell lung, non-small cell lung, colon, brain, ovarian, endometrial, triple negative breast and pancreatic. COTI-2 test results show it to be highly effective as a single agent therapy and as a combination therapy in a number of animal models of human cancers.